JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. 🌐 JAMAOncology.comhttps://bsky.app/profile/jamaoncology.comhttps://bsky.app/profile/jamaoncology.com/post/3mqubo2nvb42qIn metastatic breast cancer trials, progression-free survival by blinded central review and investigator assessment was similar, supporting use of either method for endpoint evaluation. ja.ma/4w2Lcn417 Jul 2026 17:30 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mqubo2nvb42qhttps://bsky.app/profile/jamaoncology.com/post/3mqet4zhlmm27Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. ja.ma/4vjZWNb11 Jul 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mqet4zhlmm27https://bsky.app/profile/jamaoncology.com/post/3mqchoyhwlv2oAmong patients with advanced #BiliaryTractCancer, durvalumab plus gemcitabine and cisplatin provided sustained 4-year overall survival benefit and a comparable safety profile vs placebo plus chemotherapy ja.ma/4ygxazN10 Jul 2026 15:29 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mqchoyhwlv2ohttps://bsky.app/profile/jamaoncology.com/post/3mplefxaqlf2kGenomic profiling of consecutive meningiomas found associations between copy number alterations, somatic variants, tumor grade, and patient characteristics, offering insights into prognosis and therapeutic vulnerability. ja.ma/3SGkCRU01 Jul 2026 11:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mplefxaqlf2khttps://bsky.app/profile/jamaoncology.com/post/3mp534wtkmy2hPatients with platinum-sensitive recurrent #OvarianCancer and exceptional response to PARP inhibitors showed ≥78% ten-year progression-free survival, with low risk of myeloid cancers, regardless of maintenance duration. ja.ma/44AA3h325 Jun 2026 18:36 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mp534wtkmy2hhttps://bsky.app/profile/jamaoncology.com/post/3moutkxivza23The 9-valent #HPV vaccine was linked to reduced risk of #HPVRelatedCancers in males aged 9 to 26 years, with consistent protection in both the adolescent and young adult groups. ja.ma/4uPlDod22 Jun 2026 12:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3moutkxivza23https://bsky.app/profile/jamaoncology.com/post/3mos7qqn5lg2oPretreatment MRI findings including extraprostatic extension and seminal vesicle invasion were independently prognostic for recurrence, metastasis, and mortality after radical prostatectomy. #ProstateCancer ja.ma/4xGq5Ii21 Jun 2026 11:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mos7qqn5lg2ohttps://bsky.app/profile/jamaoncology.com/post/3moppbtladx2jClonal hematopoiesis of indeterminate potential (CHIP) was associated with higher risk of trastuzumab-related cardiotoxicity and heart failure in patients with #BreastCancer. ja.ma/446aHaZ20 Jun 2026 11:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3moppbtladx2jhttps://bsky.app/profile/jamaoncology.com/post/3monnvpijgx2oAmong adults with lymphoma or myeloma, second primary malignant neoplasms after T-cell–engaging bispecific antibody therapy occurred in 3.5%, with most second primary malignant neoplasms being skin or hematologic cancers. ja.ma/3SlsYOG19 Jun 2026 15:30 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3monnvpijgx2ohttps://bsky.app/profile/jamaoncology.com/post/3monma3cz3m2dA single-fraction 19 Gy SBRT regimen for localized #ProstateCancer achieved 92.9% 3-year biochemical relapse-free survival, with grade 2 genitourinary and gastrointestinal adverse event rates below 10% and 5%, respectively, at 3 years. ja.ma/4wjqpeX19 Jun 2026 15:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3monma3cz3m2dhttps://bsky.app/profile/jamaoncology.com/post/3mofqrgxldb2vSequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy. ja.ma/4eOqlwD16 Jun 2026 12:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mofqrgxldb2vhttps://bsky.app/profile/jamaoncology.com/post/3mo6g3aloy62kA 58-year-old woman with #BreastCancer with multiple prior courses of systemic treatments presented with hypotension, hypoxia, significant polyuria, and polydipsia. Mild thickening of the pituitary stalk was seen. ✍️ What is your diagnosis? ja.ma/4vAqpXs13 Jun 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mo6g3aloy62khttps://bsky.app/profile/jamaoncology.com/post/3mo3vme725m2uThis Special Communication provides consensus recommendations on the acquisition, interpretation, and reporting of prostate magnetic resonance imaging for cancer screening. ja.ma/4eApoJc12 Jun 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mo3vme725m2uhttps://bsky.app/profile/jamaoncology.com/post/3mnzk6dystj2zAvelumab combined with methotrexate resulted in >95% durable remission and preserved #fertility in low-risk gestational trophoblastic #tumors, with a manageable safety profile. ja.ma/3RRcFcp11 Jun 2026 15:30 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mnzk6dystj2zhttps://bsky.app/profile/jamaoncology.com/post/3mnuaubgcq32pSequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy. ja.ma/4oe1whI09 Jun 2026 13:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mnuaubgcq32phttps://bsky.app/profile/jamaoncology.com/post/3mnmsss655d2rAmong patients with early age–onset #ColorectalCancer in Texas, treatment delays longer than six weeks were associated with reduced survival, and language barriers represented a major risk factor contributing to delayed initiation of definitive therapy. ja.ma/3S1igN706 Jun 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mnmsss655d2rhttps://bsky.app/profile/jamaoncology.com/post/3mnmm4a5elc2oSequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy. ja.ma/4dRk9EG06 Jun 2026 12:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mnmm4a5elc2ohttps://bsky.app/profile/jamaoncology.com/post/3mnkcduxrjf2rA phase 3 trial shows serplulimab plus chemotherapy improved overall survival and 4-year survival rates vs chemotherapy alone in extensive-stage small cell #LungCancer, with durable benefit and manageable safety. ja.ma/4x4hcrO05 Jun 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mnkcduxrjf2rhttps://bsky.app/profile/jamaoncology.com/post/3mnk3ncspws2vOral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #Dermatitis, with no serious treatment-related adverse events. ja.ma/4vAMjdf05 Jun 2026 12:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mnk3ncspws2vhttps://bsky.app/profile/jamaoncology.com/post/3mnhwvvj6ed2dA meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #NSCLC with high #PDL1, though with greater toxicity. ja.ma/43Nj4aU04 Jun 2026 15:30 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mnhwvvj6ed2dhttps://bsky.app/profile/jamaoncology.com/post/3mnawochkeu2qFrom @jama.com: In resected non-small cell lung #cancer, adjuvant #nivolumab following standard care was not associated with improved survival or recurrence risk compared with observation, even in tumors with high PD-L1 expression. #ASCO26 @ascocancer.bsky.social ja.ma/3RypEQ201 Jun 2026 20:37 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mnawochkeu2qhttps://bsky.app/profile/jamaoncology.com/post/3mnaptwyesv26A phase 3 trial demonstrated that fovinaciclib plus aromatase inhibitor showed significant and clinically improved progression-free survival with manageable safety in hormone receptor-positive, ERBB2-negative advanced #BreastCancer. #ASCO26 @ascocancer.bsky.social ja.ma/3QdaXRV01 Jun 2026 18:35 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mnaptwyesv26https://bsky.app/profile/jamaoncology.com/post/3mn5ssp3amj2bAmong women with breast cancer gene pathogenic variants (PV), most would not have received high-risk screening based on clinical or polygenic risk, supporting the need for germline PV testing in risk-based #BreastCancer screening. #ASCO26 @ascocancer.bsky.social ja.ma/4dVLSD631 May 2026 14:50 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mn5ssp3amj2bhttps://bsky.app/profile/jamaoncology.com/post/3mn5ronzwu72dOlder adults with advanced cancer mainly prioritized quality of life, but their treatment preferences were not associated with differences in survival, hospitalization, or adverse effects. ja.ma/3RwiJH531 May 2026 14:29 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mn5ronzwu72dhttps://bsky.app/profile/jamaoncology.com/post/3mn3fmg2rz52dStudy of veterans with cancer identified high rates of suicidal self-directed violence, with greatest risk in younger, female, American Indian or Alaska Native, and those with central nervous system, pancreas, liver, thyroid, or head and neck cancer. ja.ma/3PAJSrL30 May 2026 15:48 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mn3fmg2rz52dhttps://bsky.app/profile/jamaoncology.com/post/3mn3ffsqfjc23This JAMA Oncology Review examines the clinical utility of circulating tumor DNA assays for detecting minimal residual disease in patients with early-stage breast cancer. ja.ma/4dJKUte30 May 2026 15:44 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mn3ffsqfjc23https://bsky.app/profile/jamaoncology.com/post/3mn3f4ngcfe2kSequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy. ja.ma/4dQBSea30 May 2026 15:39 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mn3f4ngcfe2khttps://bsky.app/profile/jamaoncology.com/post/3mmojuivzxq2xLocal salvage therapies alone for #ProstateCancer recurrence after radiotherapy maintained >75% androgen deprivation therapy–free survival at 2 years with manageable rates of severe adverse events, supporting their use in selected patients. ja.ma/4dFl2Pk25 May 2026 13:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mmojuivzxq2xhttps://bsky.app/profile/jamaoncology.com/post/3mmogj6aure24💬 Editorial: Stereotactic radiation offered modest symptom relief & better long-term neurocognitive outcomes than hippocampal-avoidance whole brain radiation, but was associated with higher rates of new brain metastases & salvage whole brain radiotherapy. ja.ma/49lWhq625 May 2026 12:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mmogj6aure24https://bsky.app/profile/jamaoncology.com/post/3mmm4qtszik27Relabeling grade group 1 #ProstateCancer as precancerous was predicted to decrease US mortality, with six times more deaths avoided through increased screening than caused by reduced surveillance adherence. ja.ma/49hD8Wk24 May 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mmm4qtszik27